Of the few preclinical IPOs, Metagenomi keeps details about IND plans close
28 Mar 2024
IPOGene Therapy
There’s no word yet on when Metagenomi will enter the clinic.
In its first quarterly update as a public company, the California biotech said Wednesday that its cash runway is set to take it into 2027 and bankroll two INDs along the way, but it was mum on when the first study could begin.
That didn’t surprise analysts since Metagenomi went public last month in one of the most high-profile preclinical IPOs in recent memory. The company is attempting to find new enzymes and create gene-editing tools.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.